Greco C, Ameglio F, Alvino S, Cianciulli A M, Giovannelli M, Mattei F, Vitelli G, Venturo I, Lopez M, Gandolfo G M
Clinical Pathology Laboratory, National Cancer Institute of Rome, Italy.
Acta Haematol. 1994;92(1):1-7. doi: 10.1159/000204128.
Serum levels of various immunochemical markers of clinical interest, as interleukin-6 (IL-6), C-reactive protein (CRP) and beta 2-microglobulin (beta 2M), were measured in sera from 98 subjects affected with monoclonal gammopathy of undetermined significance (MGUS; 80% of which bearing cancer too) and from 39 patients with multiple myeloma (MM). In addition, the ratio between serum IgG/IgA amounts (GAR) was also calculated in monoclonal gammopathies of IgG type. Consistent with our previous investigations, we found that tumor presence significantly influenced the serum levels of the various markers (except GAR) in MGUS patients; in fact, only when comparing MGUS without tumor and MM patients, was a clear difference observed for all markers considered. The data presented discourage the use of IL-6, CRP and beta 2M as discriminant indices between MGUS and MM patients, unless a careful selection of MGUS subjects is performed. Further investigations on these potential markers are therefore needed for a more rational clinical application.
在98例意义未明的单克隆丙种球蛋白病（MGUS；其中80%也患有癌症）患者和39例多发性骨髓瘤（MM）患者的血清中，检测了多种具有临床意义的免疫化学标志物的血清水平，如白细胞介素-6（IL-6）、C反应蛋白（CRP）和β2-微球蛋白（β2M）。此外，还计算了IgG型单克隆丙种球蛋白病患者血清IgG/IgA量之比（GAR）。与我们之前的研究一致，我们发现肿瘤的存在显著影响MGUS患者各种标志物（除GAR外）的血清水平；事实上，只有在比较无肿瘤的MGUS患者和MM患者时，才观察到所有考虑的标志物存在明显差异。除非对MGUS患者进行仔细筛选，否则本文所呈现的数据不支持将IL-6、CRP和β2M用作MGUS和MM患者之间的鉴别指标。因此，需要对这些潜在标志物进行进一步研究，以便更合理地应用于临床。
